Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
New diet drugs are making it easier to lose weight. So does that mean we can stop exercising? Health experts say no. There is ...
Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...
Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.
The weight loss market is evolving at an unprecedented rate with the advancements in anti-obesity medications, and 2025 will ...
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback